IPW
INKT icon

Impact Partnership Wealth’s MiNK Therapeutics INKT Stock Holding History

Impact Partnership Wealth’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1
Closed -$13 – 1112
2023
Q2 		$13 Buy
+1
New +$20 ﹤0.01% 917

Other funds holding INKT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Impact Partnership Wealth's INKT Position: Q3 2023 in Review

Impact Partnership Wealth sold out of MiNK Therapeutics (INKT) in Q3 2023, closing a stake of 1 share — an estimated $13 sold.

Impact Partnership Wealth first reported a position in INKT in Q2 2023 and held it in 1 quarter. The position peaked at $13 in Q2 2023. 34 funds tracked by Wall St. Rank hold INKT as of Q3 2023.

  • Impact Partnership Wealth reported no remaining MiNK Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Impact Partnership Wealth sold 1 MiNK Therapeutics share in Q3 2023, an estimated $13.
  • Impact Partnership Wealth first reported a position in MiNK Therapeutics in Q2 2023 and held it in 1 quarter.
  • Impact Partnership Wealth's MiNK Therapeutics position peaked at $13 in Q2 2023.
  • 34 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q3 2023.

Based on Impact Partnership Wealth's 13F filing for Q3 2023, filed 17 Oct 2023.